Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Peginterferon alfacon-1
- Development stage
- Phase 4
- Lead developer
- Amgen
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Peginterferon alfacon-1 is a bio-engineered type I interferon alpha that has been PEGylated (chemically attached to polyethylene glycol chains) to improve its pharmacokinetic properties. It is FDA-approved for the treatment of chronic hepatitis C infection. The drug acts by binding to type I interferon receptors (IFNAR1 and IFNAR2), activating the JAK/STAT signaling pathway, which leads to upregulation of hundreds of interferon-stimulated genes with antiviral and immunomodulatory effects. These actions result in increased presentation of viral antigens, activation of cytotoxic T lymphocytes, inhibition of viral replication, and modulation of immune responses[1][2][6][8].
- Brand names
- Infergen
- Other names
- interferon alfacon-1pegylated interferon alfacon-1
02
Targets
IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on Peginterferon alfacon-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Peginterferon alfacon-1.